From September, Eli Lilly will raise the UK price of its diabetes and weight-loss drug Mounjaro by as much as 170%. The US pharmaceutical giant says the increase will align UK costs with those in other developed nations and address “pricing disparities.”

The NHS will not be affected for now. The price surge is aimed at private patients and providers, who often negotiate discounts behind closed clinic doors. But for those paying out of pocket, the jump is steep, the highest monthly dose will soar from £122 to £330, while lower doses will rise by 45 to 138 per cent.

For many, this is more than a wallet shock. It could mean rethinking whether to continue treatment, especially since Mounjaro is often taken long term to maintain results. With so much at stake, here’s a closer look at what the drug does, who it’s for, and the benefits and risks to consider.

What is Mounjaro?

Mounjaro, the brand name for tirzepatide, is an injectable medication, notes Diabetes UK, and is approved in the UK for type 2 diabetes and, more recently, for obesity. It is part of a newer class of drugs that not only control blood sugar but also promote significant weight loss.

Unlike earlier medications such as Ozempic and Wegovy, both of which were based on semaglutide, Mounjaro works by activating two hormone receptors: GLP-1 and GIP, at the same time. This “dual agonist” approach appears to produce greater weight loss than single-receptor drugs.

How Does it Work?

Mounjaro increases levels of natural hormones called incretins. These hormones help the body release more insulin when needed, reduce glucose production by the liver, and slow digestion so you feel fuller for longer.

The result is a two-pronged effect:

Better blood sugar control in people with type 2 diabetes

Reduced appetite and calorie intake leading to weight loss

In clinical trials, people taking the highest dose (15 mg weekly) lost up to 21 per cent of their body weight. That’s on par with some bariatric surgeries, but without the invasive procedure.

Who Can Take Mounjaro?

For type 2 diabetes

Adults aged 18 and over who have not been able to control blood sugar with other medications, or who cannot tolerate them due to side effects or other conditions.

Typically prescribed if the person also has a BMI of 35 kg/m² or higher with obesity-related health issues, though exceptions exist for those with lower BMIs in certain ethnic groups or specific medical needs.

For obesity

In England and Wales: Recommended for people with a BMI of at least 35 kg/m² and related health conditions, including type 2 diabetes. Lower thresholds apply for some ethnic groups.

In Scotland: Available for people with a BMI of at least 30 kg/m² plus one obesity-related condition.

The Benefits

Significant weight loss that can improve or reverse obesity-related health problems

Improved blood sugar control in people with type 2 diabetes

Once-weekly dosing with a pre-filled pen for convenience

May reduce risk of complications from diabetes, though more research is ongoing for cardiovascular benefits

The Risks and Side Effects

Like other drugs in its class, Mounjaro can cause:

• Nausea, vomiting, diarrhoea, constipation, indigestion
• Risk of low blood sugar if taken with insulin or certain other diabetes drugs
• Possible risk of high blood sugar if insulin doses are cut too quickly
• In animal studies, an increased risk of thyroid tumors, whether this applies to humans is still unknown

Long-term safety data is limited since the drug is relatively new. Some people may also regain weight if they stop taking it.

Cost and Access Challenges

On the NHS, Mounjaro is free for those eligible under treatment guidelines, but rollout is gradual due to costs and support service limitations. Access for weight loss alone is prioritized for those with the highest clinical need.

Private prescriptions vary in cost and availability. After the September price hike, the financial burden will be significant for many patients, especially since ongoing treatment is often required to maintain benefits.

Life Without the Jab

If the higher cost puts Mounjaro out of reach, lifestyle changes can still deliver meaningful results. Strategies that mimic some of its effects include:

• Eating high-protein meals to promote satiety
• Choosing high-fibre foods to slow digestion
• Limiting ultra-processed foods that spike blood sugar
• Regular physical activity to improve insulin sensitivity

A new study has discovered that use of antibiotics during pregnancy may raise the risk of babies developing Group B Streptococcus (GBS) disease.

Researchers from Sweden's Karolinska Institutet in Sweden and University of Antwerp in Belgium found prenatal antibiotic exposure to be associated with an increased risk of neonatal GBS disease by about 30 percent within four weeks of delivery. Exposure during early third trimester made the newborns most susceptible.

They scientists noted, "Prenatal antibiotic exposure can raise GBS risk within four weeks postpartum, especially in neonates not covered by risk-based intrapartum prophylaxis, with the early third trimester being a critical window of susceptibility."

What Is Group B Streptococcus (GBS) disease?

Most babies born to women carrying group B strep in their body are health but the few who are infected during labor can become very ill. The illness caused by group B strep can start within six hours of birth (early-onset disease) or three weeks after birth (late-onset disease).

Common symptoms include:

• Fever.
• Low body temperature.
• Trouble feeding.
• Sluggishness, limpness or weak muscle tone.
• Trouble breathing.
• Irritable behavior.
• Jittery movements.
• Seizures.
• Rash.
• Jaundice.

Universal prenatal screening around 36-37 weeks of pregnancy can help prevent the development of GBS disease in babies. The illness is typically treated with antibiotics.

What Did The Study Find?

The researchers conducted a population-based cohort study on 1,095,644 singleton live births in Sweden from 2006 to 2016 using national registers.

Among those, prenatal antibiotic exposure was recorded in 24.5 percent, of which 4.9 percent were exposed in more than one trimester. During the study period, the overall incidence of GBS disease was 0.71 per 1,000 live births.

Compared with unexposed newborns, GBS incidence within four weeks postpartum was higher among exposed newborns (0.86 per 1,000 live births) for an increased risk of 29%.

Among pregnancies without any GBS risk factors, prenatal antibiotic exposure was associated with a 34% higher risk of GBS disease.

Despite clear results, the authors noted it’s too early to draw causal conclusions more research into the links between antibiotics and GBS disease development is needed.

The researchers said, "Given the widespread use of antibiotics during pregnancy (~25% of pregnancies globally), rising GBS resistance, and the lack of licensed maternal GBS vaccine, this potential association warrants further studies."

This study was published in January 2026 in Journal of Infection.

In a recent episode of Soha Ali Khan’s YouTube podcast 'All About Her', actor Bhumi Pednekkar clarified that she has not used any weigh-loss drugs or injectables to lose over 40kgs of weight and credited her transformation to a balanced lifestyle.

The Dum Laga Ke Haisha star told Khan, "People have even asked me if I’ve had a rib removed. What about the fact that I’ve put 10 years into working out and eating right? In Delhi, women straight up come to me and ask, ‘Aapne bhi Ozempic ya Mounjaro liya hai?’

"I know enough people who have taken Ozempic and genuinely needed that medical assistance, so I will never judge anyone for it. But the fact is, I lost 40 kg and more without injectables.”

Pednekkar, 36, went on to also express annoyance over the rumors of her weight loss and noted that her battle against dengue in 2023 forced her to lose 12kgs.

"So basically, for this other character, I lost a lot of weight. I was in hospital recovering from dengue. I lost 12 kg and half my hair. The pain you go through is unmatched. It was Diwali and people were bursting crackers, while I had a splitting headache until I reached the hospital," she said.

How did Pednekkar lose weight?

For her workouts, she likes to mix things up with different workouts such as Pilates, running, strength training and weight training and completes nearly 8,000 steps on average every day.

What Are Ozempic and Mounjaro?

Ozempic (semaglutide) is a prescription injectable GLP-1 medication primarily approved for adults with Type 2 diabetes to manage blood sugar levels. However, the drug has gained immense popularity among those trying to lose weight as it can reduce hunger and help people feel full for longer, which forces the body to burn fat deposits to stay functional.

In clinical trials, people with obesity using semaglutide have shown to lose an average of about 15% of their body weight over 68 weeks. Most people begin to see noticeable results within 8 to 12 weeks of taking the drug.

The official price in India for a once-weekly Ozempic injection pen ranges from approximately ₹8,800 for the 0.25 mg dose to around ₹11,175 for the 1 mg dose per month. Insurance coverage is generally inconsistent for weight loss indications.

Similarly to Ozempic, Mounjaro mimics two natural gut hormones, GLP-1 and GIP, to regulate blood sugar, reduce appetite, slow digestion and provide the body with a feeling of fullness, leading to reduced calorie intake.

Clinical trials have shown that participants using Mounjaro along with lifestyle changes can lose up to 15-22% of their body weight over the span of 72 weeks.

Eli Lilly launched Mounjaro in India in March 2025 in the form of vials and released KwikPen versions of the drug later in August 2025. Monthly costs for KwikPens range from approximately ₹14,000 to ₹27,500.

Common side effects of both weigh-loss drugs include gastrointestinal issues, nausea, vomiting, diarrhea and constipation. More serious but rare side effects can include pancreatitis and gallbladder issues.

Typhoid fever, to many sound like it now belongs to history books, but a new strain that can resist strongest of antibiotics have emerged in South Asia. This has raised the concerns over the potential spread of drug-resistant infections.

A gene, which is capable of breaking down carbapenems, which is a powerful antibiotics was seen as a drug of last resort, is discovered among 32 samples collected from hospitals, across western and southern India. This gene is known as blaNDM-5, which can move between different types of bacteria, raising fears that resistance could in fact grow quickly.

Recent outbreaks of extensively drug-resistant (XDR) typhoid across South Asia have raised serious concerns, as these strains no longer respond to most commonly used antibiotics. Since 2016, Pakistan alone has reported over 15,000 XDR typhoid cases, while resistance to azithromycin has been detected in Bangladesh, India, Nepal and other neighboring regions.

Speaking to the Telegraph, Dr Malick Gibani, Clinical Lecturer in Infectious Diseases at Imperial College London, said, “We all hear that antimicrobial resistance is a problem, but typhoid really exemplifies it – how resistance seems to emerge relentlessly, moving from one class of antibiotics to the next."

“It’s not yet untreatable, but the treatments we do have are much more limited and significantly more challenging to deliver.”

What Is Typhoid?

Typhoid is caused by the bacteria Salmonella Typhi. It usually spreads through contaminated food or water and can lead to high fever, stomach pain and serious complications if not treated on time.

Antibiotics are the first line of treatment. These range from commonly used medicines such as amoxicillin and co-trimoxazole to stronger, hospital-only drugs for resistant infections, including carbapenems. Without timely treatment, typhoid can turn life-threatening and, in some cases, prove fatal. What has alarmed researchers is the emergence of typhoid strains that can resist even carbapenems.

“Although the number of cases described is still relatively small, this feels very much like a warning sign,” said Dr Gibani. “This was always expected and reflects the steady evolution of antimicrobial resistance in typhoid. These infections are not untreatable yet, but they are becoming increasingly difficult to manage.”

Experts point out that typhoid is often difficult to diagnose. This uncertainty can lead to the widespread and sometimes unnecessary use of antibiotics, which further fuels resistance. There are also concerns that extensively drug-resistant typhoid may be more widespread than current data suggests, especially in low-income countries where surveillance and reporting are limited.

“The risk is highest in places with poor water quality, uncontrolled antibiotic use and weak healthcare systems,” said Prof Calman A. MacLennan from the University of Oxford. He noted that while current typhoid mortality is under one percent, the disease was far deadlier before antibiotics were available. “In the pre-antibiotic era, death rates were as high as 10 to 20 percent, and during some wars, more people died of typhoid than from combat.”

Best Line Of Defense Against Typhoid

Vaccination, experts say, could be key to preventing a resurgence. The Typhoid Conjugate Vaccine, or TCV, has shown strong effectiveness by triggering the body’s immune response rather than targeting the bacteria directly with antibiotics. “That makes it much harder for the pathogen to escape,” Prof MacLennan explained.

The vaccine has already been introduced into national immunization programmes in 11 countries. However, reaching the poorest regions, where typhoid is most common, remains a challenge. Rolling out a new vaccine requires significant planning and resources, even with international support.

Dr Gibani warned that although South Asia has been hit hardest so far, drug-resistant typhoid can spread globally through travel. Imported cases have already been reported in Europe, North America and Australia. Experts stress that surveillance, vaccination and better sanitation are critical to stopping these dangerous strains from taking hold elsewhere.